HLA-DRB2: A Promising Drug Target / Biomarker (G3124)

Target Name: HLA-DRB2

NCBI ID: G3124

HLA-DRB2

Other Name(s): HLA-DR2B | major histocompatibility complex, class II, DR beta 2 (pseudogene) | MGC120245 | Major histocompatibility complex, class II, DR beta 2 (pseudogene)

HLA-DRB2: A Promising Drug Target / Biomarker

HLA-DRB2 is a human leukocyte antigen (HLA) gene that is located on chromosome 6p21. It is a key regulator of immune responses and has been implicated in a number of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. The HLA-DRB2 gene has also been identified as a potential drug target and biomarker for a number of diseases, including cancer.

Background

HLA-DRB2 is a member of the major histocompatibility complex (MHC) genes, which are responsible for the presentation of antigens from the body's immune system to T cells. The HLA-DRB2 gene is located on chromosome 6p21 and has been shown to encode a protein that is involved in the presentation of antigens to T cells.

Expression of HLA-DRB2

HLA-DRB2 is expressed in a wide variety of tissues and cells in the body, including blood cells, tissue cells, and immune cells. It is also expressed in the skin, eyes, and nervous system, and has been shown to be involved in the immune response to a variety of stimuli, including viruses, bacteria, and cancer cells.

Disease associations

HLA-DRB2 has been implicated in a number of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. These conditions involve an overactive immune response that leads to inflammation and damage in the body. HLA-DRB2 has been shown to play a role in the development and progression of these diseases by regulating the immune response and promoting the production of immune cells that are involved in inflammation.

In addition to its involvement in autoimmune diseases, HLA-DRB2 has also been shown to be involved in cancer. For example, studies have shown that HLA-DRB2 is often expressed in human cancer cells and that it may be a potential biomarker for cancer progression.

Drug targeting

HLA-DRB2 has also been identified as a potential drug target for a number of diseases. For example, researchers have shown that inhibiting the activity of HLA-DRB2 can be an effective way to treat autoimmune diseases, including rheumatoid arthritis and lupus.

In addition, HLA-DRB2 has also been shown to be involved in the development of cancer, and inhibiting its activity may be an effective way to treat cancer. For example, studies have shown that inhibiting the activity of HLA-DRB2 has been effective in treating a variety of cancers, including breast, ovarian, and skin cancers.

Biomarker potential

HLA-DRB2 has also been shown to be involved in the immune response and may be a potential biomarker for a number of diseases. For example, studies have shown that HLA-DRB2 is often expressed in the immune cells that are involved in inflammation, and that its activity may be involved in the development of autoimmune diseases.

In addition, HLA-DRB2 has also been shown to be involved in the development of cancer, and its activity may be involved in the development of cancer. For example, studies have shown that HLA-DRB2 is often expressed in cancer cells and that its activity may be involved in the development and progression of cancer.

Conclusion

HLA-DRB2 is a gene that has been shown to be involved in the immune response and may be a potential drug target or biomarker for a number of diseases. Its activity has been implicated in a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis, as well as cancer. Further research is needed to fully understand the role of HLA-DRB2 in the immune response and its potential as a drug target or biomarker.

Protein Name: Major Histocompatibility Complex, Class II, DR Beta 2 (pseudogene)

The "HLA-DRB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DRB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets